4D Molecular Therapeutics FDMT Other operating expenses
Other operating expenses at other companies
Other financials
Where this comes from
Reported directly by 4D Molecular Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The official record: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about 4D Molecular Therapeutics's other operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is 4D Molecular Therapeutics's other operating expenses?
- 4D Molecular Therapeutics (FDMT) reported other operating expenses of $76.67M in Q1 2026.
- How has 4D Molecular Therapeutics's other operating expenses changed year-over-year?
- 4D Molecular Therapeutics's other operating expenses increased by 42.9% year-over-year, from $53.64M to $76.67M.
- What is the long-term trend for 4D Molecular Therapeutics's other operating expenses?
- Over 4 years (2021 to 2025), 4D Molecular Therapeutics's other operating expenses has grown at a 28.6% compound annual growth rate (CAGR), from $89.37M to $244.76M.
- What does other operating expenses mean?
- Residual operating expenses not classified into specific categories, serving as a catch-all for miscellaneous operating costs.